Bone Biologics closes $3.0 million private placement, extends runway to Q2 2027
Bone Biologics said it completed a July 2026 private placement with one healthcare-focused institutional investor, with gross proceeds of about $3.0 million before fees and expenses. The company says the financing extends its operating runway through Q2 2027, and the filing contains no revenue or earnings figures.
Key points
- July 2026 private placement with a single healthcare-focused institutional investor, priced at-the-market under Nasdaq rules, for gross proceeds of about $3.0 million before fees and expenses
- Series F and G warrants could add up to about $6.0 million if fully exercised for cash, but the company gives no assurance that any will be exercised
- Company expects to complete patient enrollment in its first-in-human NB1 pilot study by year-end
- Validated shelf life of rhNELL-1 extended to 29 months in May 2026, up from 24 months in December 2025
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 23, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.